The last time I spoke about Inhibrx Biosciences, Inc. (INBX) it was in a Seeking Alpha article entitled "Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing." With respect to ...

SAN DIEGO, Oct. 23, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The chondrosarcoma market is anticipated to increase during the forecast period (2026–2036), owing to improved diagnosis, treatment advancements, increased awareness, the launch of emerging therapies ...

Bone sarcomas are rare heterogeneous tumors that affect patients of all ages including children, adolescent young adults, and older adults. They include many aggressive subtypes and patient groups ...

Among patients with chondrosarcomas, the most common primary bone tumor in adults, the presence of a TP53 gene mutation has been found to be associated with worse overall survival and metastasis-free ...

Metastatic cancer is cancer that has spread from its original location to a distant part of the body. Most metastatic cancers are not curable, but people with well-controlled metastatic cancer can ...

Ozekibart meets its primary endpoint in chondrosarcoma, demonstrating a statistically significant and clinically meaningful improvement in median progression-free survival compared to placebo Key ...

SAN DIEGO, April 21, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic ...

SAN DIEGO, April 20, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for ...